---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-028123"
form_type: "8-K"
ticker: "SLDB"
cik: "0001707502"
company_name: "Solid Biosciences Inc."
filed_at: "2025-02-18T23:59:59+00:00"
generated_at: "2026-05-26T16:46:53.496283+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Solid Biosciences reports 110% avg microdystrophin expression from SGT-003 Phase 1/2 trial

## Summary
- First three participants showed average 110% microdystrophin expression by western blot and 78% dystrophin-positive fibers at Day 90.
- Mean reductions in muscle injury biomarkers: CK -57%, AST -45%, ALT -54%, LDH -60% at Day 90.
- Two participants at Day 180 showed mean LVEF increase of 8% from baseline; no serious adverse events or TMA observed.
- Preliminary cash, cash equivalents and available-for-sale securities of ~$148.9M as of Dec 31, 2024.
- Company plans mid-2025 FDA meeting to discuss accelerated approval for SGT-003; enrollment ongoing with 7th dosed Feb 17.

## SEC filing metadata
- accession: 0001193125-25-028123
- form_type: 8-K
- ticker: SLDB
- cik: 0001707502
- company_name: Solid Biosciences Inc.
- filed_at: 2025-02-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1707502/000119312525028123/0001193125-25-028123-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1707502/000119312525028123/d913726d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-028123
- JSON: https://secwatch.observer/filing/0001193125-25-028123.json
- Plain text: https://secwatch.observer/filing/0001193125-25-028123.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.